Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALADDIN
NCT06468995Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cabotegravir and rilpivirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoints: Feasibility of Implementation Measure at 11 months, Acceptability of Intervention Measure at 11 months and 2 more. Started Dec 2024; status: completed.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06468995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06468995.